Increased susceptibility to Aβ toxicity in neuronal cultures derived from familial Alzheimer's disease (PSEN1-A246E) induced pluripotent stem cells

Neuroscience Letters

Volumn 639, Issue , 2017, Pages 74-81

  Armijo, Enrique ^a,b   Gonzalez, Cesar ^a   Shahnawaz, Mohammad ^a   Flores, Andrea ^a   Davis, Brian ^a   Soto, Claudio ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSIDAD DE LOS ANDES   (Chile)

Author keywords

Alzheimer's disease; Amyloid beta; Induced pluripotent stem cells; Neurotoxicity

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; OLIGOMER; AMYLOID BETA PROTEIN;

ADULT; ALZHEIMER DISEASE; ARTICLE; CASE REPORT; CONTROLLED STUDY; DISEASE PREDISPOSITION; HUMAN; HUMAN CELL; MALE; MIDDLE AGED; NERVE CELL CULTURE; NEUROTOXICITY; PLURIPOTENT STEM CELL LINE; PRIORITY JOURNAL; SKIN FIBROBLAST; TOXICITY ASSAY; BRAIN; CELL CULTURE; CELL DIFFERENTIATION; CHEMICALLY INDUCED; CYTOLOGY; DRUG EFFECTS; FIBROBLAST; GENETICS; INDUCED PLURIPOTENT STEM CELL; METABOLISM; NERVE CELL; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BRAIN; CELL DIFFERENTIATION; CELLS, CULTURED; DISEASE SUSCEPTIBILITY; FIBROBLASTS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MALE; MIDDLE AGED; NEURONS;

EID: 85007614141     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2016.12.060     Document Type: Article

References (59)

1. [1] Borchelt, D.R., Thinakaran, G., Eckman, C.B., Lee, M.K., Davenport, F., Ratovitsky, T., Prada, C.M., Kim, G., Seekins, S., Yager, D., Slunt, H.H., Wang, R., Seeger, M., Levey, A.I., Gandy, S.E., Copeland, N.G., Jenkins, N.A., Price, D.L., Younkin, S.G., Sisodia, S.S., Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17 (1996), 1005–1013.
2. [2] Burd, J.F., Usategui-Gomez, M., A colorimetric assay for serum lactate dehydrogenase. Clin. Chim. Acta 46 (1973), 223–227.
3. [3] Cao, S.S., Kaufman, R.J., Endoplasmic reticulum stress and oxidative stress in cell fate decision and human disease. Antioxid. Redox Signal. 21 (2014), 396–413.
4. [4] Caughey, B., Lansbury, P.T., Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 26 (2003), 267–298.
5. [5] Chen, Y.R., Glabe, C.G., Distinct early folding and aggregation properties of Alzheimer amyloid-beta peptides Abeta40 and Abeta42: stable trimer or tetramer formation by Abeta42. J. Biol. Chem. 281 (2006), 24414–24422.
6. [6] Chiti, F., Dobson, C.M., Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 75 (2006), 333–366.
7. [7] Costa, R.O., Lacor, P.N., Ferreira, I.L., Resende, R., Auberson, Y.P., Klein, W.L., Oliveira, C.R., Rego, A.C., Pereira, C.M., Endoplasmic reticulum stress occurs downstream of GluN2B subunit of N-methyl-D-aspartate receptor in mature hippocampal cultures treated with amyloid-beta oligomers. Aging Cell 11 (2012), 823–833.
8. [8] Domingues, A., Almeida, S., da Cruz e Silva, E.F., Oliveira, C.R., Rego, A.C., Toxicity of beta-amyloid in HEK293 cells expressing NR1/NR2A or NR1/NR2B N-methyl-D-aspartate receptor subunits. Neurochem. Int. 50 (2007), 872–880.
9. [9] Ferreira, S.T., Vieira, M.N., De Felice, F.G., Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB Life 59 (2007), 332–345.
10. [10] Ferri, C.P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., Jorm, A., Mathers, C., Menezes, P.R., Rimmer, E., Scazufca, M., I. Alzheimer's Disease, Global prevalence of dementia: a Delphi consensus study. Lancet 366 (2005), 2112–2117.
11. [11] Haass, C., Selkoe, D.J., Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8 (2007), 101–112.
12. [12] Hebert, L.E., Weuve, J., Scherr, P.A., Evans, D.A., Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology 80 (2013), 1778–1783.
13. [13] Henriques, A.G., Vieira, S.I., da Cruz, E.S.E.F., da Cruz, E.S.O.A., Abeta promotes Alzheimer's disease-like cytoskeleton abnormalities with consequences to APP processing in neurons. J. Neurochem. 113 (2010), 761–771.
14. [14] Imaizumi, Y., Okano, H., Modeling human neurological disorders with induced pluripotent stem cells. J. Neurochem. 129 (2014), 388–399.
15. [15] Israel, M.A., Yuan, S.H., Bardy, C., Reyna, S.M., Mu, Y., Herrera, C., Hefferan, M.P., Van Gorp, S., Nazor, K.L., Boscolo, F.S., Carson, C.T., Laurent, L.C., Marsala, M., Gage, F.H., Remes, A.M., Koo, E.H., Goldstein, L.S., Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 482 (2012), 216–220.
16. [16] Ivins, K.J., Ivins, J.K., Sharp, J.P., Cotman, C.W., Multiple pathways of apoptosis in PC12 cells. CrmA inhibits apoptosis induced by beta-amyloid. J. Biol. Chem. 274 (1999), 2107–2112.
17. [17] Katayama, T., Imaizumi, K., Sato, N., Miyoshi, K., Kudo, T., Hitomi, J., Morihara, T., Yoneda, T., Gomi, F., Mori, Y., Nakano, Y., Takeda, J., Tsuda, T., Itoyama, Y., Murayama, O., Takashima, A., St George-Hyslop, P., Takeda, M., Tohyama, M., Presenilin-1 mutations downregulate the signalling pathway of the unfolded-protein response. Nat. Cell Biol. 1 (1999), 479–485.
18. [18] Kayed, R., Lasagna-Reeves, C.A., Molecular mechanisms of amyloid oligomers toxicity. J. Alzheimers Dis. 33:Suppl. 1 (2013), S67–78.
19. [19] Klein, W.L., Krafft, G.A., Finch, C.E., Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?. Trends Neurosci. 24 (2001), 219–224.
20. [20] Kondo, T., Asai, M., Tsukita, K., Kutoku, Y., Ohsawa, Y., Sunada, Y., Imamura, K., Egawa, N., Yahata, N., Okita, K., Takahashi, K., Asaka, I., Aoi, T., Watanabe, A., Watanabe, K., Kadoya, C., Nakano, R., Watanabe, D., Maruyama, K., Hori, O., Hibino, S., Choshi, T., Nakahata, T., Hioki, H., Kaneko, T., Naitoh, M., Yoshikawa, K., Yamawaki, S., Suzuki, S., Hata, R., Ueno, S., Seki, T., Kobayashi, K., Toda, T., Murakami, K., Irie, K., Klein, W.L., Mori, H., Asada, T., Takahashi, R., Iwata, N., Yamanaka, S., Inoue, H., Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Abeta and differential drug responsiveness. Cell Stem Cell 12 (2013), 487–496.
21. [21] Kuo, Y.M., Emmerling, M.R., Vigo-Pelfrey, C., Kasunic, T.C., Kirkpatrick, J.B., Murdoch, G.H., Ball, M.J., Roher, A.E., Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J. Biol. Chem. 271 (1996), 4077–4081.
22. [22] Lacor, P.N., Buniel, M.C., Chang, L., Fernandez, S.J., Gong, Y., Viola, K.L., Lambert, M.P., Velasco, P.T., Bigio, E.H., Finch, C.E., Krafft, G.A., Klein, W.L., Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J. Neurosci. 24 (2004), 10191–10200.
23. [23] Lacor, P.N., Buniel, M.C., Furlow, P.W., Clemente, A.S., Velasco, P.T., Wood, M., Viola, K.L., Klein, W.L., Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J. Neurosci. 27 (2007), 796–807.
24. [24] LaFerla, F.M., Green, K.N., Oddo, S., Intracellular amyloid-beta in Alzheimer's disease. Nat. Rev. Neurosci. 8 (2007), 499–509.
25. [25] Lesne, S., Koh, M.T., Kotilinek, L., Kayed, R., Glabe, C.G., Yang, A., Gallagher, M., Ashe, K.H., A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440 (2006), 352–357.
26. [26] Lesne, S.E., Sherman, M.A., Grant, M., Kuskowski, M., Schneider, J.A., Bennett, D.A., Ashe, K.H., Brain amyloid-beta oligomers in ageing and Alzheimer's disease. Brain 136 (2013), 1383–1398.
27. [27] Li, J.Q., Yu, J.T., Jiang, T., Tan, L., Endoplasmic reticulum dysfunction in Alzheimer's disease. Mol. Neurobiol. 51 (2015), 383–395.
28. [28] Li, W., Sun, W., Zhang, Y., Wei, W., Ambasudhan, R., Xia, P., Talantova, M., Lin, T., Kim, J., Wang, X., Kim, W.R., Lipton, S.A., Zhang, K., Ding, S., Rapid induction and long-term self-renewal of primitive neural precursors from human embryonic stem cells by small molecule inhibitors. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 8299–8304.
29. [29] Loo, D.T., Copani, A., Pike, C.J., Whittemore, E.R., Walencewicz, A.J., Cotman, C.W., Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. Proc. Natl. Acad. Sci. U. S. A. 90 (1993), 7951–7955.
30. [30] Lue, L.F., Kuo, Y.M., Roher, A.E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J.H., Rydel, R.E., Rogers, J., Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155 (1999), 853–862.
31. [31] McLean, C.A., Cherny, R.A., Fraser, F.W., Fuller, S.J., Smith, M.J., Beyreuther, K., Bush, A.I., Masters, C.L., Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46 (1999), 860–866.
32. [32] Mohmmad Abdul, H., Sultana, R., Keller, J.N., St Clair, D.K., Markesbery, W.R., Butterfield, D.A., Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid beta-peptide (1-42), HO and kainic acid: implications for Alzheimer's disease. J. Neurochem. 96 (2006), 1322–1335.
33. [33] Naslund, J., Haroutunian, V., Mohs, R., Davis, K.L., Davies, P., Greengard, P., Buxbaum, J.D., Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283 (2000), 1571–1577.
34. [34] Nethercott, H.E., Brick, D.J., Schwartz, P.H., Derivation of induced pluripotent stem cells by lentiviral transduction. Methods Mol. Biol. 767 (2011), 67–85.
35. [35] Nilsen, J., Chen, S., Irwin, R.W., Iwamoto, S., Brinton, R.D., Estrogen protects neuronal cells from amyloid beta-induced apoptosis via regulation of mitochondrial proteins and function. BMC Neurosci., 7, 2006, 74.
36. [36] Oyama, F., Sawamura, N., Kobayashi, K., Morishima-Kawashima, M., Kuramochi, T., Ito, M., Tomita, T., Maruyama, K., Saido, T.C., Iwatsubo, T., Capell, A., Walter, J., Grunberg, J., Ueyama, Y., Haass, C., Ihara, Y., Mutant presenilin 2 transgenic mouse: effect on an age-dependent increase of amyloid beta-protein 42 in the brain. J. Neurochem. 71 (1998), 313–322.
37. [37] Querfurth, H.W., LaFerla, F.M., Alzheimer's disease. N. Engl. J. Med. 362 (2010), 329–344.
38. [38] Rammes, G., Hasenjager, A., Sroka-Saidi, K., Deussing, J.M., Parsons, C.G., Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of beta-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices. Neuropharmacology 60 (2011), 982–990.
39. [39] Resende, R., Ferreiro, E., Pereira, C., Oliveira, C.R., ER stress is involved in Abeta-induced GSK-3beta activation and tau phosphorylation. J. Neurosci. Res. 86 (2008), 2091–2099.
40. [40] Sakono, M., Zako, T., Amyloid oligomers: formation and toxicity of Abeta oligomers. FEBS J. 277 (2010), 1348–1358.
41. [41] Sandoe, J., Eggan, K., Opportunities and challenges of pluripotent stem cell neurodegenerative disease models. Nat. Neurosci. 16 (2013), 780–789.
42. [42] Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T.D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, E., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D., Younkin, S., Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2 (1996), 864–870.
43. [43] Shankar, G.M., Leissring, M.A., Adame, A., Sun, X., Spooner, E., Masliah, E., Selkoe, D.J., Lemere, C.A., Walsh, D.M., Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. Neurobiol. Dis. 36 (2009), 293–302.
44. [44] Shaughnessy, L., Chamblin, B., McMahon, L., Nair, A., Thomas, M.B., Wakefield, J., Koentgen, F., Ramabhadran, R., Novel approaches to models of Alzheimer's disease pathology for drug screening and development. J. Mol. Neurosci. 24 (2004), 23–32.
45. [45] Sherrington, R., Rogaev, E.I., Liang, Y., Rogaeva, E.A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., Tsuda, T., Mar, L., Foncin, J.F., Bruni, A.C., Montesi, M.P., Sorbi, S., Rainero, I., Pinessi, L., Nee, L., Chumakov, I., Pollen, D., Brookes, A., Sanseau, P., Polinsky, R.J., Wasco, W., Da Silva, H.A., Haines, J.L., Perkicak-Vance, M.A., Tanzi, R.E., Roses, A.D., Fraser, P.E., Rommens, J.M., St George-Hyslop, P.H., Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375 (1995), 754–760.
46. [46] Shi, Y., Kirwan, P., Smith, J., MacLean, G., Orkin, S.H., Livesey, F.J., A human stem cell model of early Alzheimer's disease pathology in down syndrome. Sci. Transl. Med., 4, 2012, 124ra129.
47. [47] Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., Yamanaka, S., Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131 (2007), 861–872.
48. [48] Takahashi, K., Yamanaka, S., Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126 (2006), 663–676.
49. [49] Tomita, T., Maruyama, K., Saido, T.C., Kume, H., Shinozaki, K., Tokuhiro, S., Capell, A., Walter, J., Grunberg, J., Haass, C., Iwatsubo, T., Obata, K., The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue. Proc. Natl. Acad. Sci. U. S. A. 94 (1997), 2025–2030.
50. [50] Vazin, T., Ball, K.A., Lu, H., Park, H., Ataeijannati, Y., Head-Gordon, T., Poo, M.M., Schaffer, D.V., Efficient derivation of cortical glutamatergic neurons from human pluripotent stem cells: a model system to study neurotoxicity in Alzheimer's disease. Neurobiol. Dis. 62 (2014), 62–72.
51. [51] Viola, K.L., Velasco, P.T., Klein, W.L., Why Alzheimer's is a disease of memory: the attack on synapses by A beta oligomers (ADDLs). J. Nutr. Health Aging 12 (2008), 51S–57S.
52. [52] Walsh, D.M., Klyubin, I., Fadeeva, J.V., Rowan, M.J., Selkoe, D.J., Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem. Soc. Trans. 30 (2002), 552–557.
53. [53] Walsh, D.M., Selkoe, D.J., A beta oligomers – a decade of discovery. J. Neurochem. 101 (2007), 1172–1184.
54. [54] Walsh, D.M., Tseng, B.P., Rydel, R.E., Podlisny, M.B., Selkoe, D.J., The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry 39 (2000), 10831–10839.
55. [55] Walsh, R.M., Hochedlinger, K., Modeling Rett syndrome with stem cells. Cell 143 (2010), 499–500.
56. [56] Wogulis, M., Wright, S., Cunningham, D., Chilcote, T., Powell, K., Rydel, R.E., Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death. J. Neurosci. 25 (2005), 1071–1080.
57. [57] Xu, X., Lei, Y., Luo, J., Wang, J., Zhang, S., Yang, X.J., Sun, M., Nuwaysir, E., Fan, G., Zhao, J., Lei, L., Zhong, Z., Prevention of beta-amyloid induced toxicity in human iPS cell-derived neurons by inhibition of cyclin-dependent kinases and associated cell cycle events. Stem Cell Res. 10 (2013), 213–227.
58. [58] Yagi, T., Ito, D., Okada, Y., Akamatsu, W., Nihei, Y., Yoshizaki, T., Yamanaka, S., Okano, H., Suzuki, N., Modeling familial Alzheimer's disease with induced pluripotent stem cells. Hum. Mol. Genet. 20 (2011), 4530–4539.
59. [59] Yazawa, M., Dolmetsch, R.E., Modeling Timothy syndrome with iPS cells. J. Cardiovasc. Transl. Res. 6 (2013), 1–9.